Codexis and Arch expand collaboration
Biocatalysis specialist Codexis and Indian active pharmaceutical ingredients (APIs) and intermediates manufacturer, Arch Pharmalabs have expanded their three-year partnership in pharmaceuticals manufacturing
Biocatalysis specialist Codexis and Indian active pharmaceutical ingredients (APIs) and intermediates manufacturer, Arch Pharmalabs have expanded their three-year partnership in pharmaceuticals manufacturing
Codexis, based in Redwood City, CA, will offer multiple pharmaceutical intermediates and active pharmaceutical ingredients (APIs) made with its proprietary biocatalytic processes to both innovator and generic drug manufacturers.
Sales in India will be through its subsidiary, Codexis Laboratories India Private Limited. Arch, which is based in Mumbai, India and has 10 facilities throughout the country, will be Codexis' exclusive manufacturer for these products. The two companies will also co-market products.
"Codexis and Arch will now offer a broad range of competitively-priced drug ingredients to the global pharmaceutical industry. We believe this collaboration offers a major opportunity for growth," said Alan Shaw, Ph.D., president and ceo of Codexis.
Products to be sold under the new collaboration include the full range of intermediates used to manufacture generic atorvastatin, as well as the API itself. Atorvastatin is the active ingredient in Lipitor, the world's largest selling drug used to lower cholesterol. Other planned future products include generic intermediates and APIs for montelukast (asthma/allergy) and esomeprazole (ulcers), as well as a key intermediate used in the manufacture of the carbapenem class of antibiotics.
